The initial success of the copyright undeniably revolutionized the pharmaceutical landscape, but investing in companies primarily reliant on off-patent versions presents a complex picture. Although early returns were significant, the end of patents and the rise of discounted alternatives have eroded sales. Thus, a thorough assessment of current fin